The Weekly Summary

lavrov-kerry_2668937bSeptember 9th – September 15th

In general news, a diplomatic breakthrough was reached to allow Syria to destroy chemical weapons rather than have the U.S. strike. In the U.S., Twitter began the IPO process.

In healthcare business news, Forest Labs (FRX) new CEO is the former Bausch&Lomb CEO. Delcath (DCTH) ousted their CEO. Roche partnered with Inovio (INO). Fresenius (FMS) acquired hospitals from Rhoen-Klinikum for $4 Billion. More bad press sent Intuitive Surgical (ISRG) shares down. Bayer is the latest drug company to be investigated by China for bribery of foreign officials. Lastly, CBS News reporting caused the Medicare fraudsters at The Scooter Store to close down.

On the data front, Biodel’s (BIOD) attempt to make a super-rapid-acting insulin was set back with bad data, sending shares down. MannKind’s (MNKD) Afrezza remains the most likely super-rapid-acting insulin to be approved.

From the FDA, an advisory committee voted to approve Roche’s breast cancer drug Perjeta, and also Glaxo’s (GSK) Anoro Elipta inhaler. Allergan’s (AGN) Botox was approved for crow’s feet lines, which will have little impact since almost all doctors use it there currently. Lastly, Delcath (DCTH) was dealt the final blow when the FDA rejected the filing for ocular melanoma Melblez Kit.

This entry was posted in - The Weekly Summary. Bookmark the permalink.

Leave a Reply

Your email address will not be published.